TrialPath
Recruiting

The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

NCT07612878 · Sanofi
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
This registry will enroll 350 participants with COPD newly initiated in dupilumab over a period of approximately 12 months at approximately 20 US sites experienced in the diagnosis and treatment of COPD. Data, chest images, and home spirometries will be collected from participants for approximately 2 years. Participant management and treatment decisions will be determined by participants and their health care professionals.
Eligibility criteria
Inclusion Criteria: * COPD patients who are newly referred to start dupilumab treatment * Age ≥ 40 years * Standard of care spirometry performed concurrently with the baseline visit or within 90 days prior to the baseline visit Exclusion Criteria: * Patients who have contraindication to dupilumab according to the United States Prescribing Information (USPI) * Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments * Patients currently participating in any interventional clinical trial The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Study design
Enrollment target: 350 participants
Age groups: adult, older_adult
Timeline
Starts: 2026-08-06
Estimated completion: 2029-11-30
Last updated: 2026-10-15
Interventions
Drug: Cohort 1: DupilumabOther: Cohort 2: usual care only
Primary outcomes
  • • Participant Characteristics (End of study (24 months after the last participant is enrolled))
  • • Participant Characteristics (End of study (24 months after the last participant is enrolled))
  • • Patient Characteristics (End of study (24 months after the last participant is enrolled))
Sponsor
Sanofi · industry
Contacts & investigators
ContactTrial Transparency Trial Transparency · contact · Contact-us@sanofi.com · 800-633-1610 option 6
All locations (7)
IU Health Pulmonology & Critical Care MedicineRecruiting
Indianapolis, Indiana, United States
University of KansasRecruiting
Lawrence, Kansas, United States
DukeRecruiting
Durham, North Carolina, United States
Ohio State UniversityRecruiting
Columbus, Ohio, United States
The Respire InstituteRecruiting
Houston, Texas, United States
Activian Clinical ResearchRecruiting
Kingwood, Texas, United States
The Lung & Sleep Institute of North TexasRecruiting
North Richland Hills, Texas, United States
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry · TrialPath